Karyotakis N C, Anaissie E J
Department of Medical Specialties, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Antimicrob Agents Chemother. 1994 Nov;38(11):2660-2. doi: 10.1128/AAC.38.11.2660.
Immunosuppressed CF1 mice were infected intravenously with two strains of Candida krusei and four strains of Candida lusitaniae (two of which were resistant to amphotericin B). Mice were treated with 1 or 2 mg of amphotericin B desoxycholate per kg of body weight per day or escalating doses of liposomal amphotericin B (8 to 30 mg/kg/day) or were left untreated. Higher doses of liposomal amphotericin B were as effective as standard dose of amphotericin B desoxycholate in prolonging survival but were significantly more effective in reducing the fungal burden in the kidneys of animals infected with both C. krusei strains and the C. lusitaniae strains that were susceptible to amphotericin B desoxycholate. This advantage of liposomal amphotericin B therapy could not be demonstrated in mice infected with the C. lusitaniae strains that were resistant to amphotericin B desoxycholate.
免疫抑制的CF1小鼠通过静脉注射感染了两株克鲁斯念珠菌和四株葡萄牙念珠菌（其中两株对两性霉素B耐药）。小鼠每天按每千克体重1或2毫克的剂量接受去氧胆酸两性霉素B治疗，或接受递增剂量的两性霉素B脂质体治疗（8至30毫克/千克/天），或不接受治疗。更高剂量的两性霉素B脂质体在延长生存期方面与标准剂量的去氧胆酸两性霉素B一样有效，但在降低感染了两株克鲁斯念珠菌以及对去氧胆酸两性霉素B敏感的葡萄牙念珠菌菌株的动物肾脏中的真菌负荷方面，效果显著更好。在感染了对去氧胆酸两性霉素B耐药的葡萄牙念珠菌菌株的小鼠中，无法证明两性霉素B脂质体治疗的这一优势。
